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Summary
 
Recently, major advances have been made in the identification of antigens from human mela-
noma which are recognized by T cells. In spite of this, little is known about the optimal ways
to use these antigens to treat patients with cancer. Progress in this area is likely to require accu-
rate preclinical animal models, but the availability of such models has lagged behind develop-
ments in human tumor immunology. Whereas many of the identified human melanoma anti-
gens are normal tissue differentiation proteins, analogous murine tumor antigens have not yet
been identified. In this paper we identify a normal tissue differentiation antigen, tyrosinase-
related protein 2 (TRP-2), expressed by the murine B16 melanoma which was found by
screening a cDNA library from B16 with tumor-reactive cytotoxic T lymphocytes (CTL). A
peptide conforming to the predicted MHC class I H2-K
 
b
 
 binding motif, TRP-2
 
181-188
 
, was
identified as the major reactive epitope within TRP-2 recognized by these anti-B16 CTLs. By
site-directed mutagenesis, it was shown that alteration of this epitope eliminated recognition of
TRP-2. It was further demonstrated that a CTL line raised from splenocytes by repeated stim-
ulation in vitro with this peptide could recognize B16 tumor and was therapeutic against 3-d-old
established pulmonary metastases. The use of TRP-2 in a preclinical model of tumor immuno-
therapy may be helpful in suggesting optimal vaccination strategies for cancer therapy in pa-
tients.
 
A
 
number of studies have suggested that T cell responses
  to tumor-associated antigens can be of therapeutic
benefit both in animals and in patients with cancer. Clinical
trials demonstrated that 35% of patients with melanoma
treated with specific, tumor-reactive, tumor-infiltrating lym-
phocytes and IL-2 achieved either partial or complete tu-
mor regression (1). A class of nonmutated, melanocyte lin-
eage normal differentiation proteins including tyrosinase
(2, 3), tyrosinase-related protein (TRP)
 
1
 
-1 (4), melanoma
antigen reactive with T cells (MART)-1 (5), and gp100 (6)
proved to be widely recognized in an MHC class I–restricted
fashion by tumor-reactive T cells from different patients.
Current protocols are directed at using these widely expressed
antigens in vaccination trials for patients with melanoma,
although it has been difficult to rationally choose clinical
therapeutic strategies because of the growing list of antigens
and the multitude of immunizing vectors, adjuvants, and
supportive cytokines which have been elucidated.
Accurate animal models may be valuable in better de-
signing vaccination strategies. Existing models are limited
by a relatively small number of known antigens, few of
which are analogous to known antigens in human cancers.
Murine tumor–associated antigens have been shown to in-
clude mutated proteins such as connexin 37 from the Lewis
lung carcinoma, and proteins expressed only in tumor and
testis or placenta such as P1A from the P815 mastocytoma.
Although similar antigens have been found in human tu-
mors, these antigens are either not shared (i.e., are unique
to one patient), or are poorly immunogenic.
To better understand the immune response to cancer
and to design immunotherapeutic strategies, efforts are un-
derway to clone antigens from murine tumors which are
recognized by T cells. In this paper, we report that T cells
reactive with the B16 murine melanoma recognize a non-
mutated product of the TRP-2 gene. This murine mela-
noma–associated antigen may be useful in designing vac-
cine and combination therapies to treat patients with
melanoma.
 
Materials and Methods
 
Cell Lines.
 
The murine melanoma B16 is a spontaneously
arising melanoma of C57BL/6 mice propagated by Dr. I.J. Fidler
(M.D. Anderson Cancer Center, Houston, TX), which was cul-
tured in complete media (CM) consisting of RPMI 1640 medium
 
1
 
Abbreviations used in this paper:
 
 CM, complete media; gal, galactosidase;
MART, melanoma antigen reactive with T cells; TRP, tyrosinase-related
protein.
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(Biofluids, Inc., Rockville, MD) supplemented with the following:
10% heat-inactivated fetal calf serum (Biofluids, Inc.), 0.1 mM
nonessential amino acids and 1 mM sodium pyruvate (Biofluids,
Inc.), 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol (GIBCO BRL, Gaithers-
burg, MD), 0.3% glutamine (National Institutes of Health Media
Unit, Bethesda, MD), 100 U/ml penicillin, 100 
 
m
 
g/ml strepto-
mycin, 50 
 
m
 
g/ml gentamicin, and 0.5 
 
m
 
g/ml fungizone. A B16
tumor line expressing the murine co-stimulatory molecule B7.1
was generated in our laboratory using a Moloney leukemia virus-
based retroviral vector (LXSN) containing murine B7.1 (CD80).
The B7.1 cDNA used was a gift from Dr. R. Germain (National
Institute of Allergy and Infectious Diseases, Bethesda, MD). The
transformed human embryonic kidney line 293 was purchased
from the American Type Culture Collection (Rockville, MD),
and grown in DMEM medium containing 5% heat-inactivated
fetal calf serum, 0.3% glutamine, 0.01 M Hepes (National Insti-
tutes of Health Media Unit), 100 U/ml penicillin, and 100 
 
m
 
g/ml
streptomycin. The murine thymoma EL-4 (and a variant trans-
fected with the 
 
b
 
-galactosidase [gal] gene, E22), and the murine
colon carcinoma MC38, were grown in CM. The immortalized
melanocyte line melan-A was a gift of Dr. V. Hearing (National
Cancer Institute, Bethesda, MD), and was grown in Bennett’s
medium, pH 6.9, which consisted of MEM (GIBCO BRL), 5%
heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 25 mM
sodium bicarbonate, 100 
 
m
 
M 2-mercaptoethanol, 200 nM PMA
(Sigma Chemical Co., St. Louis, MO), 50 U/ml penicillin, and
50 
 
m
 
g/ml streptomycin.
 
Generation of Tumor-reactive T Cell Lines.
 
Female C57BL/6 mice
were obtained from Charles River Laboratories (Raleigh, NC) and
used when 6–12 wk old. Tumor-reactive T cell lines were gener-
ated as follows. Mice were immunized with 1 
 
3
 
 10
 
6
 
 irradiated
(20,000 cGy) B16 tumor cells and 50 
 
m
 
g 
 
Corynebacterium parvum.
 
2 wk later, spleens were harvested and crushed with the blunt end
of a syringe in the presence of ACK lysis buffer. The suspension
was passed through 100-gauge nylon mesh (Nitex), washed
twice, and plated in 24-well plates at 4 
 
3
 
 10
 
6
 
 per well with 2 
 
3
 
10
 
5
 
 irradiated B16 cells expressing murine B7.1 (B16
 
?
 
B7). Recom-
binant human IL-2 (Chiron Corp., Emeryville, CA) at 30 IU/ml
was added after 2 d, and cultures were restimulated weekly with
B16
 
?
 
B7 and refed every 3 d with medium containing IL-2. Sev-
eral lines reactive with B16 were obtained in this manner, and
one was selected for use based on its degree of reactivity and pro-
liferation (designated 
 
line A
 
).
 
Generation of Peptide-reactive T Cell Lines.
 
Splenocytes from nor-
mal mice or mice vaccinated with irradiated B16 and 
 
C. parvum
 
were obtained as described above and cultured in CM with 5 
 
m
 
g/ml
of purified peptide at a density of 4 
 
3
 
 10
 
6
 
 per well in 24-well
plates. On the second day of culture, IL-2 was added to a final
concentration of 30 IU/ml. After 8–10 d of culture, nonviable
cells were removed with a discontinuous lympholyte-M gradient
(Accurate Chemical and Scientific Corp., Westbury, NY), and
lymphocytes were washed and replaced in fresh CM with 30 IU/
ml of IL-2 at 8 
 
3
 
 10
 
5
 
 cells/well. Stimulator cells were then gen-
erated by incubating 5 
 
3
 
 10
 
7
 
 fresh splenocytes in CM with 5
 
m
 
g/ml of peptide for 90 min, washing with HBSS (Biofluids
Inc.), and resuspending in CM. After 2,000 cGy irradiation, 3 
 
3
 
10
 
6
 
 of these irradiated, peptide-pulsed splenocytes were added to
each well of the culture to be stimulated. IL-2 and CM were par-
tially replaced every 2–3 d, and repeated antigen stimulation was
performed every 7–10 d. Cultures were typically tested and used
after at least one in vitro restimulation.
 
Lymphocyte Adoptive Transfer Treatment Model.
 
Recipient C57BL/6
mice were first given 500 cGy whole body irradiation to suppress
any endogenous responses to B16 or IL-2 and then were adminis-
tered 3 
 
3
 
 10
 
5
 
 B16 cells in HBSS by tail vein injection on day 0.
On day three, 1–2 
 
3
 
 10
 
6
 
 of the CTLs being evaluated for efficacy
were administered intravenously and 6 
 
3
 
 10
 
4
 
 IU IL-2 was ad-
ministered intraperitoneally three times per day for 3 d. On days
13–17, mice were killed and the number of metastases were eval-
uated in a coded, blinded fashion. Differences in the numbers of
metastases were analyzed by the Kruskal-Wallis test and all 
 
P
 
 val-
ues are two-tailed.
 
cDNA Expression Cloning and Screening.
 
Total RNA from B16
cells was extracted using the RNAzol B isolation system (Tel-Test,
Friendswood, TX). mRNA was isolated using the Promega
PolyATract mRNA isolation system (Promega Corp., Madison
WI). Double-stranded cDNA was made using the NOVAGEN
random primer directional cDNA library kit (Novagen, Inc., Madi-
son, WI). After the addition of linkers, the cDNA was digested
with EcoRI and HindIII to ensure proper unidirectional sense
orientation during ligation. cDNA was size-selected at 
 
.
 
800 bp
on a 1.0% agarose gel before ligation. The cDNA was recovered
using a Glass Select DNA Isolation Kit (5 Prime–3 Prime Inc.,
Boulder, CO), and cloned into the pcDNA3 vector (Invitrogen,
San Diego, CA).
cDNA was electroporated into ElectroMAX DH10B 
 
Escheri-
chia coli
 
 (GIBCO BRL) and grown in selection media for 48 h.
Plasmid DNA was purified using the Wizard Series 9600 System
(Promega Corp.) at a density of 25 clones/well in 96-well plates.
200 ng of each DNA pool and 2 
 
m
 
g lipofectamine (GIBCO
BRL) were added to 4 
 
3
 
 10
 
4
 
 293 cells previously transfected and
selected to stably express the murine class I MHC molecules
H2-K
 
b
 
 and H2-D
 
b
 
 (designated 293K
 
b
 
D
 
b
 
) in a 96-well plate with
150 
 
m
 
l of transfection media consisting of DMEM with 10 mM
Hepes and 0.3% glutamine. After 2 h, an equal volume of trans-
fection media 
 
1
 
 10% fetal calf serum was added to the lipid–
DNA mixture. After overnight incubation, the media was re-
moved and 4 
 
3
 
 10
 
4
 
 line A cells were added to these 293K
 
b
 
D
 
b
 
cells in 250 
 
m
 
l of CM. After 24 h, 100 
 
m
 
l of supernatant was col-
lected and the amount of mIFN-
 
g
 
 was measured in a standard
ELISA (Endogen, Inc., Woburn, MA) in which 1 U mIFN-
 
g
 
 
 
5
 
100 pg/ml. Individual cDNA clones were isolated from pools re-
peatedly showing reactivity above background. The cDNA in-
serts of the reactive clones were sequenced on an automated se-
quencer (ABI Prizm 310; Perkin-Elmer Corp., Foster City, CA).
Sequences were compared to the Gen-Bank database using the
BLAST search engine (7).
 
Northern Blot Analysis.
 
Total cellular RNA was isolated using
RNAzol (Tel-Test). 20 
 
m
 
g of RNA were electrophoresed on a
0.6% formaldehyde-agarose gel and transferred to a nitrocellulose
membrane. Radioactive probes were prepared using the Prime-It
RmT Random Primer Kit (Stratagene, La Jolla, CA). After hy-
bridization, membranes were washed at high stringency for 20
min at 65
 
8
 
C in 0.1
 
3
 
 SSC 
 
1
 
 0.1% SDS buffer.
 
Peptide Synthesis and Testing.
 
Peptides were synthesized on a
multiple peptide synthesizer (Gilson AMS 422; Gilson Co., Inc.,
Worthington, OH) using standard F-moc chemistry. Larger quan-
tities of selected peptides were obtained from Peptide Technologies
Corporation (Gaithersburg, MD) and HPLC-purified to 
 
.
 
98%
purity. For testing, peptides were added at 10 
 
m
 
g/ml to stimulator
cells and incubated for 90 min at room temperature. They were
then added to effector cells and IFN-
 
g
 
 release measured.
 
Reverse Transcription–PCR for TRP-2.
 
Approximately 10
 
7
 
 cul-
tured cells were lysed with TRIzol Reagent (GIBCO BRL). Total
RNA was collected, and first strand cDNA synthesis was performed
with the SuperScript Preamplification System (GIBCO BRL) us- 
455
 
Bloom et al.
ing oligo(dT)12-18 primers. PCR was performed using an optimally
matched primer pair (5
 
9
 
-CAGAACTCAGGAGTGGAAGA-3
 
9
 
)
and (5
 
9
 
-CAAGATGAGCGACGGTGTAA-3
 
9
 
) which generated
a 1,691-bp fragment containing the entire protein coding region
of murine TRP-2.
 
Site-directed Mutagenesis.
 
A Chameleon Double Stranded Site-
Directed Mutagenesis Kit (Stratagene) was used to alter the nu-
cleotide sequence for the amino acids at positions 5 and/or 8 of the
TRP-2
 
181-188
 
 epitope VYDFFVWL of TRP-2. Two mutated
TRP-2 clones were made, one used the primer (5
 
9
 
-GCAGCGT-
GTATGACTTTGATGTGTGGCTCC-3
 
9
 
) to change phenylala-
nine at position 5 to aspartic acid, and the other used the primer
(5
 
9
 
-GCGTGTATGACTTTGATGTGTGGCGCCATTATTA-
TTC-3
 
9
 
) to change position 5 as above and to also change the
leucine at position 8 to tyrosine. Mutant clones were identified
using restriction enzyme digestions with EcoRI and ScaI and
confirmed by sequencing.
 
Results
 
Several B16-reactive lines were obtained from the sple-
nocytes of mice immunized with irradiated B16 tumor and
cocultured with B16
 
?
 
B7 and IL-2. One line was selected
based on its reactivity and in vitro expansion potential. This
bulk lymphocyte culture (line A) showed preferential rec-
ognition of B16 tumor in vitro as measured by IFN-
 
g
 
 re-
lease (Fig. 1), and was specifically lytic for B16 (45% lysis in
4 h at an effector/target ratio of 5:1; data not shown).
When adoptively transferred into mice bearing 3-d-old
pulmonary metastases, line A significantly reduced the number
of metastases compared to mice given IL-2 alone (
 
P
 
 
 
,
 
0.001)
or mice administered both IL-2 and CTL that recognized
the 
 
b
 
-gal protein (raised in a similar fashion to line A using
the 
 
b
 
-gal–expressing variant of EL-4, E22) (
 
P
 
 
 
,
 
0.01)
(Table 1).
To identify the antigens of B16 which were being rec-
ognized by line A, a cDNA library from B16 tumor was
screened by transiently transfecting pools of 
 
z
 
25 cDNA
clones into 293K
 
b
 
D
 
b
 
 cells and coincubating these cells with
line A CTLs. Upon screening 
 
z
 
1,000 pools, five pools that
consistently stimulated mIFN-
 
g
 
 release from line A T cells
were identified. Individual clones that stimulated cytokine
release from Line A T cells after transfection into target
cells were then isolated and sequenced. All five clones were
fragments of murine TRP-2. The locations and sizes of the
five fragments are compared to the composite cDNA se-
quence of TRP-2 reported by I. Jackson et al. (8) in Fig. 2.
Clone 3.6 contained the full-length protein coding se-
quence (bp 405–1955). Clone 2.9 represented a truncated
fragment that did not contain the normal starting methio-
nine of the TRP-2 protein. The clones 5.3 and 7.8 had
identical sequences. A fifth sequence, 6.4, represented a
truncated TRP-2 clone. A 622-bp sequence extending from
mRNA bp 534 to 1155 was shared by all of the isolates.
Northern blot analysis was performed to examine the
patterns of tissue expression of TRP-2. A probe made from
the clone 2.9 insert hybridized with a 2.2-kb product in the
pigmented melanomas B16 (fresh and cultured) B16-F.10,
M3, and JB/MS, as well as the pigmented immortalized
murine melanocyte line, melan-A. The probe failed to hy-
bridize to the nonpigmented melanoma K1735 as well as
the following nonmelanoma tumors: Lewis lung carci-
noma, the murine thymoma EL-4, the murine colon can-
cers MC38 and CT26, the hepatoma line Hepa-1, and the
chemically induced sarcomas MCA 205 and 4JK. TRP-2
expression was not seen in normal tissues samples including
brain, heart, liver, lung, spleen, and testis. Reverse tran-
scriptase-PCR of mRNA from the normal melanocyte line
Figure 1. Stimulation of mINF-g release from line A T cells by various
murine tumor lines. 105 line A T cells and 105 tumor cells were coincu-
bated in 2 ml of CM for 24 h. Aliquots of supernatant were assayed for
mINF-g. All targets were MHC type H2b except P815, 9873, and CT26
(H2d). Line A CTLs demonstrated relative specificity for the B16 tumor.
 
Table 1.
 
Treatment of 3-d-old Pulmonary Metastases from B16 by Adoptive Transfer of Anti-B16 Line A T Cells
 
Cells Transferred Systemic IL-2 Metastases per mouse Mean
None
 
2.
 
250,
 
 .
 
250, 
 
.
 
250, 
 
.
 
250, .250 .250
None 1 218, .250, .250, .250, .250, .250, .250, .250
.250, .250,.250, .250, .250, .250, .250
Line A 1 4, 23, 35, 60, 184 61*
anti–b-gal 1. 250, .250, .250, .250, .250 .250
*P ,0.001 vs. IL-2 alone, and P ,0.01 vs. b-gal CTLs.456 A Normal Differentiation Protein Is a B16 Melanoma Tumor Rejection Antigen
melan-A followed by sequencing showed it to be identical
with clone 3.6 from B16, but both of these sequences dif-
fered from the reported sequence of TRP-2 in Gen-Bank
between nucleotides 1189 and 1192. The sequence of clone
3.6 (and melan-A) was GCTG, whereas the sequence re-
ported for TRP-2 gene in Gen-Bank was CTGG. Al-
though the reason for this discrepancy has not been re-
solved, it occurs outside of the 622-bp region shared by the
five TRP-2 fragments that stimulated line A.
The MHC class I restriction element used by line A for
the recognition of TRP-2 was investigated by transient
transfection of TRP-2 into 293 cells expressing either H2-Kb
and H2-Db, H2-Kb alone, or the human MHC molecule
A2 (293 cells expressing H2-Db alone were not available).
IFN-g release by line A was similar when 293KbDb or
293Kb were transfected with TRP-2, but absent when the
control 293-A2 was used (Table 2). These results supported
the presence of at least one epitope recognized by line A in
the context of H2-Kb.
Peptides of eight amino acids from TRP-2 were then
synthesized using the H2-Kb binding motif described by
Rammensee (9, 10). 15 such peptides were identified in
the normal reading frame of TRP-2. MC38 murine tumor
cells expressing high levels of H2-Kb were incubated with
each of these peptides and tested for their ability to stimu-
late line A T cells. Only one peptide, VYDFFVWL (TRP-
2181–188) mediated line A recognition of peptide-pulsed
MC38. MC38 incubated with TRP-2181–188 caused a re-
lease of 6.0 U/ml/24 h of IFN-g from line A versus <1.0
U/ml/24 h for the other 15 peptides tested, and 0.6 U/ml/
24 h for MC38 without peptide. The nucleotides coding
for TRP-2181–188 are contained within the 622-bp sequence
common to all five of the clones identified by cDNA li-
brary screening. Peptide concentrations of 100 ng/ml or
higher were required for stimulation of cytokine release
from line A T cells (Fig. 3).
To determine whether TRP-2 represented an immu-
nodominant antigen of B16, 12 independent CTL cultures
were generated from mice by using the same methodology
used to produce line A, and were tested for their reactivity
to TRP-2. Of these 12 cultures, 10 were reactive with
TRP-2 by cytokine-release assay, which was best demon-
strated by testing specific reactivity to target cells pulsed
with the TRP-2181–188 peptide (data not shown). This sug-
gested that not only was TRP-2 a dominant antigen, but
that TRP-2181–188 was a dominant epitope of TRP-2 for
H2b mice.
To pursue this latter finding, site-directed mutagenesis of
the full-length TRP-2 clone 3.6 was used to determine
whether other antigenic epitopes existed besides TRP-2181–188.
Figure 2. Alignment of TRP-2 inserts found by
cDNA expression library screening with anti-B16
CTLs. The top line indicates the composite TRP-2
cDNA sequence described by Jackson et al. (8).
The next line (shaded) represents the coding region
for the TRP-2 protein. The location of the five
TRP-2 cDNA clones identified are shown below
(striped).
Table 2. Determination of MHC Restriction by Transfection of 
TRP-2 cDNA Clones into 293 Cells Expressing Different
MHC Molecules
IFN-g Release
Transfected cDNA
Transfection targets
293KbDb 293Kb 293-A2
U/ml*
Clone 5.3 7.0 10.7 0.5
Clone 6.4 9.3 10.5 0.5
Clone 7.8 8.1 7.3 0.5
None 0.6 0.6 0.5
*Line A T cells were incubated with the indicated targets for 24 h and
the release of IFN-g measured.
Figure 3. Release of mIFN-g by line A when incubated with MC-38
(H2b) and varying amounts of TRP-2181–188 peptide (circles). No significant
mIFN-g release was seen when MC-38 was incubated with peptide with-
out line A (square) or with line A without peptide (triangle).457 Bloom et al.
Two separate modifications were made, the first altering both
of the anchor residues at positions 5 and 8 of TRP-2181–188,
while the second altered only the anchor residue at position
5 (position 8 is shared by a different overlapping peptide
with an H2-Kb binding motif). The eight amino acid
peptides beginning at residue 181 for those two mutated
TRP-2 molecules were thus VYDFDVWL and VYDFD-
VWR, compared to the native sequence VYDFFVWL.
The result of transfecting these two altered TRP-2 genes
into 293KbDb is seen in Table 3. The alteration of one or
both of the anchor residues abrogated the ability of T cells
to recognize transfectants expressing these products. This
suggests that recognition of the TRP-2181–188 T cell epitope
accounts for all of the reactivity to TRP-2 by line A T cells.
To determine if reactivity to TRP-2181–188 could account
for the recognition of B16 by line A, TRP-2–specific re-
activity was generated from the spleens of normal or B16-
vaccinated mice by weekly in vitro stimulation with TRP-
2181–188 peptide at 5 mg/ml as described in Materials and
Methods. After two in vitro peptide stimulations, spleno-
cytes were assayed by IFN-g release for their ability to rec-
ognize peptide and B16 tumor (Table 4). Splenocytes from
normal or immunized mice stimulated with the TRP-2181–188
peptide recognized 293KbDb pulsed with this peptide, but
not parental 293 pulsed with TRP-2181–188. The same cul-
tures also recognized B16 tumor. Lymphocytes from those
same mice incubated in parallel with the H2-Kb–presented
ovalbumin-derived peptide SIINFEKL (ova257–264) failed to
recognize B16.
The therapeutic efficacy of CTL lines generated by in
vitro stimulation with TRP-2181–188 was also examined. T
cell lines generated from normal or B16 immune mice by
stimulation with the TRP-2181–188 peptide were used to
treat 3-d-old B16 lung metastases by intravenous adminis-
tration of the CTL in combination with low dose IL-2. A
highly significant therapeutic effect was seen (P ,0.001)
with cultures from normal or B16-immunized mice when
stimulated with TRP-2181–188, but not with ova257–264 pep-
tide (when compared to treatment with IL-2 alone) (Fig. 4).
Discussion
In the last five years, much progress has been made in the
molecular identification of tumor cell proteins which are
recognized by the cellular immune system in the context of
the MHC (4–6, 11, 12). Work performed largely with pa-
tients with melanoma has identified nearly a dozen tumor-
associated antigens which can be divided into several gen-
eral categories. One group of antigens, characterized by the
MAGE (13, 14), BAGE (15), and GAGE (16) families of
Table 3. Effect of TRP-2 Mutations within TRP-2181–188 on 
Recognition by Line A T Cells when Transfected into 293 Cells 
Expressing Murine MHC Class I Molecules
IFN-g Release
Transfected cDNA
Transfection targets
293KbDb 293Kb 293
U/ml*
Clone 3.6 17.3 10.8 1.9
Clone 3.6 mut 185‡ 1.0 1.2 2.0
Clone 3.6 mut 185 1188§ 1.0 1.5 2.2
pcDNA3 0.7 1.3 2.0
*Line A T cells were incubated with the indicated targets for 24 h and
the release of IFN-g measured.
‡Amino acid185 phenylalanine substituted with aspartate.
§ Amino acid185 phenylalanine substituted with aspartate, and amino
acid188 leucine substituted with arginine.
Table 4. Reactivity of Anti–TRP-2181–188 and Anti-ovalbumin275–264 CTLs from Normal- and B16-immunized Mice with H2b-matched 
tumors and Peptide Pulsed Targets
IFN-g release
Lymphocyte culture
Tumor targets
None B16 MCA 207 MC-38
293 1
ova257–264
293 1
TPR-2181–188
293KbDb 1
ova257–264
293KbDb 1
TRP-2181–188
U/ml*
Normal spleen‡ 1 ova257–264 36 92 8 4 35 29 74 42
Immune spleen§ 1 ova257–264 14 3 5 0 9 9 1 4 9 1 1 8
Normal spleen‡ 1 TRP-2181–188 0  .600 20 9 6 3 3 .600
Immune spleen§ 1 TRP-2181–188 5 .600 77 28 12 12 11 .600
Line A T cells 0 .600 24 7 0 0 0 134
*Line A T cells were incubated with the indicated targets for 24 h and the release of IFN-g measured.
‡Normal “naive” splenocytes.
§Donor mice previously immunized 1 3 106 irradiated B16 tumor cells and 50 mg C. parvum.458 A Normal Differentiation Protein Is a B16 Melanoma Tumor Rejection Antigen
proteins, are coded for by normal nonmutated genes, and
seem to be expressed by tumor cell, testis, and sometimes
placenta, but not other normal tissues. Another major fam-
ily of antigens represents normal tissue differentiation pro-
teins because they are expressed in melanoma, normal me-
lanocytes, and pigmented retinal cells, and are typified by
the proteins tyrosinase (2, 3), TRP-1 (4), gp100 (6), and
MART-1 (5). Some tumors were also found to express a
mutated version of a normal cellular protein which forms a
“foreign” MHC-binding peptide specifically recognized by
T cells. This category of mutated tumor-associated antigen
is exemplified by both b-catenin (with a serine to phenyl-
alanine mutation at position 37; reference 11), and the mu-
tated form of cyclin-dependant kinase 4 (17).
Fewer tumor-associated antigens have been identified in
murine tumors. Nevertheless, these antigens seem to con-
form to the categories identified for human tumor–associ-
ated antigens. The P1A protein of the P815 mastocytoma is
analogous to the MAGE family of proteins in that it is en-
coded by a nonmutated gene which is expressed only in tu-
mor, testis, and placenta (18–21). The Lewis lung carci-
noma expresses a mutated form of the connexin 37 protein
which is recognized by CD81 T cells restricted by H2-Kb
(22). In the present paper, the first murine tumor–associ-
ated antigen recognized by CD81 T cells representing a
normal tissue differentiation protein has been identified. As
was the case with human gp100 and MART-1, a T cell
line with known in vivo antitumor activity was used to
screen a tumor cDNA library to identify this antigen (5, 6).
In the case of mTRP-2, CTLs with specific activity against
the TRP-2181–188 peptide were also effective in treating es-
tablished B16 tumor, supporting the hypothesis that TRP-2
reactive T cells are at least in part responsible for the in
vivo antitumor effects seen with the line A T cells.
Several future areas of investigation are generated by
these data. After a single in vitro stimulation with the
TRP-2181–188 peptide, splenocytes from normal mice, as
well as from mice immunized with irradiated B16 tumor,
showed reactivity to B16. It is not understood why naive
mice have significant numbers of CTL precursors with re-
activity to TRP-2. A search of the Gen-Bank database did
not identify any other proteins which contained the amino
acid sequence VYDFFVWL. Nevertheless, similar peptides
from other immunogenic proteins capable of mimicking
TRP-2181–188 may be involved in generating reactivity to
this “self” protein (23). The peripheral tolerance mecha-
nisms which prevent these precursors from becoming acti-
vated in vivo and mediating either B16 rejection or vitiligo
are of interest. Overcoming these tolerizing influences may
be critical to the future development of clinical immuno-
therapeutic strategies for patients with melanoma, and po-
tentially for other tumors as well. The preclinical model
delineated in this work appears to be well suited for study-
ing a variety of proposed immunization strategies directed
at achieving this goal. We are currently developing recom-
binant viral vectors containing mTRP-2, and are also study-
ing combinations of anti–TRP-2 vaccination, co-stimulation,
and systemic cytokines for the treatment of B16 melanoma.
Wang et al. have recently demonstrated that human
TRP-2 is recognized as a melanoma-associated antigen by
a T cell clone from a population of tumor infiltrating lym-
phocytes which mediated clinical tumor regression (24).
This T cell clone recognized the hTRP-2197–205 peptide of
TRP-2 in the context of HLA-A31. This finding supports
the relevance of mTRP-2 as a model tumor antigen for
preclinical studies, where it may prove useful in the plan-
ning of rational immunotherapy strategies for the treatment
of patients with cancer.
Figure 4. Treatment of 3-d-old pulmonary metastases from B16 by the
intravenous administration of T cells reactive with TRP-2181–188 gener-
ated by in vitro peptide stimulation of splenocytes from normal or B16-
immunized mice. Low-dose systemic IL-2 was given with adoptive cell
transfer. Therapeutic effects were seen from anti–TRP-2181–188 CTLs
from normal mice (P 5 0.0004 vs. IL-2 alone, and P 5 0.014 vs.
ovalbumin257–264 stimulated cultures), as well as from anti-B16 immunized
mice (P 5 0.0003 vs. IL-2 alone, and P 5 0.010 vs. ovalbumin257–264
stimulated cultures).
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